OBJECTIVE: The purpose of this study was to evaluate the efficacy and toxicity of concurrent chemor- adiotherapy (CCRT) in loco-regionally advanced cervical cancer patients. METHODS: The medical records of 24 patients were retrospectively reviewed who underwent CCRT' and 62 patients who had underwent radiation therapy alone at the Department of Obstetrics and Gynecology, Ajou University Hospital from September, 1994 to August 2000 for loco-regionally advanced cervical cancer (stage IIb-IVa and Ib-IIa with bulky tumor mass or pelvic lymph node involvement detected by magnetic resonance imaging). Radiotherapy was performed for 7 weeks during which the patients underwent radiotherapy and chemotherapy concomitantly. Chemotherapeutic regimen consisted of cisplatin (75 mg/m2 on day 1, 4) and 5-FU (1000 mg/m2 on day 2-5, 30-33). The toxicity was assessed according to the GOG toxicity criteria. RESULTS: In the CCRT group, 2 of 18 patients (11.1%) had recurrent disease. Of the 22 patients who were followed up, the overall survival rate was 83.3%, and the relapse-free survival rate was 89.9%. In the radiotherapy alone group, 19 of 61 patients (32.3%) had recurrent disease. Of the 62 patients who were followed up, the overall survival rate was 75.4% and the relapsed-free survival rate was 67.7%. Relative risk reduction rate of the death rate in the CCRT group was 66% (RR 0.34), and 32% (RR 0.68) in the recurrence rate. Acute toxicities in the CCRT group were enteritis grade 3:3 (12.5%), leukopenia grade 3:2 (8.3%), anemia grade 3:1 (4.1%) and grade 4:2 (8.3%). The acute toxicities in the radiation therapy alone group were enteritis grade 3:7 (11.3%), rectal bleeding grade 3:1 (1%). Increased acute toxicities developed in the CCRT group. CONCLUSION: This study shows improved overall survival rates and relapse-free survival rates but some increase in acute toxicity. It is suggested that CCRT be the standard treatment of loco-regionally advanced cervical cancer. Due to small size sample and short duration of follow up, further study of a large group of patients and the long term survival rate are necessary.
Anemia ; Chemoradiotherapy* ; Cisplatin ; Drug Therapy ; Enteritis ; Fluorouracil ; Follow-Up Studies ; Gynecology ; Hemorrhage ; Humans ; Leukopenia ; Lymph Nodes ; Medical Records ; Mortality ; Obstetrics ; Radiotherapy ; Recurrence ; Retrospective Studies ; Risk Reduction Behavior ; Survival Rate ; Uterine Cervical Neoplasms*

BACKGROUND: Propofol can be used to provide general anesthesia or sedation. The objectives of this study were to assess propofol as sedative agents for outpatient GI endoscopy, amnestic effects, hemodynamic state and oxygenation during the procedure. METHODS: From April and June 2000, 50 patients scheduled outpatient gastrointestinal endoscopy were enrolled in this study. 30 healthy outpatients requesting sedation at diagnostic gastroscopy were received a bolus dose of propofol 2.5 mg/kg and compared with 20 patients with non-sedation. Pulse rate, blood-pressure and arterial oxygen saturation was monitored. RESULTS: Statistically significant decrease in arterial oxygen saturation were observed since 5 min after endoscopy in patients receiving propofol (p=0.006). Patients receiving sedative endoscopy, pulse rate during endoscopy was significantly increased compared with propofol group (p=0.009). Patients receiving propofol are more tolerable than patients with non-sedative endoscopy (p=0.001), therefore all patients receiving propofol wanted the same sedative endoscopy in their next endoscopy. CONCLUSION: Propofol is believed to be a useful, safe sedative agent for upper gastrointestinal endoscopy with satisfactory sedation and conditions. However, due to its untoward effect of hypoxia, careful monitoring is recommended.
Anesthesia, General ; Anoxia ; Conscious Sedation* ; Endoscopy ; Endoscopy, Gastrointestinal* ; Gastroscopy ; Heart Rate ; Hemodynamics ; Humans ; Outpatients ; Oxygen ; Propofol*